LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2026 RESULTS
LSL Pharma Group has reported record-breaking revenues for the first quarter of 2026, buoyed by acquisitions of Juno OTC and Du-Var. Despite a temporary production halt at the company’s Steri-Med facility, LSL Pharma swiftly resumed operations and is poised for continued growth in key segments such as eye-care and private-label products.